Key result
Volanesorsen effectively reduces triglycerides in severe hypertriglyceridemia, potentially decreasing the risk of acute pancreatitis, though its use is associated with thrombocytopenia.
Why the study?
Severe hypertriglyceridemia treatment is challenging as conventional therapies often fail to prevent acute pancreatitis, motivating the evaluation of the APOC3 inhibitor volanesorsen.
Does volanesorsen reduce triglycerides in patients with severe hypertriglyceridemia and Familial Chylomicronemia Syndrome?
Does volanesorsen reduce triglycerides in patients with severe hypertriglyceridemia and Familial Chylomicronemia Syndrome?
Volanesorsen is an effective treatment for reducing triglycerides in Familial Chylomicronemia Syndrome, though its use requires caution due to the risk of thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
May warrant volanesorsen with platelet monitoring in FCS; leaves open randomized confirmation of pancreatitis prevention.
D’Erasmo et al. (2020) conducted a review in Severe hypertriglyceridemia (sHTG). Volanesorsen was evaluated. Volanesorsen effectively reduces triglycerides in severe hypertriglyceridemia, potentially decreasing the risk of acute pancreatitis, though its use is associated with thrombocytopenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: